Company news
Allarity Therapeutics, Inc. news in 2024
Allarity Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
November 17, 2024
Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights
November 13, 2024
Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib
October 21, 2024
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
October 9, 2024
Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program
October 2, 2024
Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial
September 15, 2024
Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 12, 2024
Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)
September 10, 2024
Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting
July 25, 2024
Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized Shares
July 23, 2024
Allarity Therapeutics Outlines Company’s 2024 Progress and Objectives
July 21, 2024
Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance
June 26, 2024
Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
June 24, 2024
Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
May 19, 2024
Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances
May 13, 2024
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
May 6, 2024
Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1
May 5, 2024
Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
May 1, 2024
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
April 16, 2024
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
April 3, 2024
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
March 26, 2024
Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)
March 24, 2024
Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update
March 7, 2024
Allarity Therapeutics to Present at Biomarkers 2024
February 27, 2024
Decks in 2024
- Corporate Update (February 2024)
Corporate update · 16 slides · February 2024